Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 7/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346163 | 0.78 | NOTUM (0.42) | MAPTNOTUMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4322903 | 0.78 | ENPP3 (0.42) | MAPTLMNAPKMNOTUMRAB9A | |
| SCHEMBL4317407 | 0.78 | KIF11 (0.45) | LMNANOTUMKIF11RAB9ANPC1 | |
| SCHEMBL973674 | 0.76 | CYP2A6 (0.50) | MAPTLMNATP53RAB9ANPC1 | |
| SCHEMBL3283855 | 0.74 | NPC1 (0.46) | MAPTLMNAPKMRAB9ANPC1 | |
| SCHEMBL3937636 | 0.69 | AHR (0.48) | MAPTTP53NOTUMRAB9ANPC1 | |
| SCHEMBL2407790 | 0.68 | CYP1A2 (0.51) | MAPTLMNATP53PKMRAB9A | |
| SCHEMBL10000032 | 0.66 | MAPT (0.92) | MAPTLMNATP53PKMNOTUM | |
| SCHEMBL135626 | 0.66 | MAPT (0.92) | MAPTLMNATP53PKMNOTUM | |
| SCHEMBL13363884 | 0.64 | CYP1A2 (0.46) | MAPTLMNATP53PKMIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009137380-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-12 | — | — | WO | claimed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | claimed |
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | BASF SE (DE) | 2011-02-17 | — | — | US | disclosed |
| WO-2009137380-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | TPMT, NQO2, TST | MAPT 4182/4885LMNA 3704/4885TP53 2061/4885 |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | MAPT 3175/4885LMNA 2521/4885TP53 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.